Description: A Phase 1 / 2 Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
Target Patient Population: Most Solid Tumors
Study Design: Drug is given IV every 3 weeks